10x Genomics (TXG) Common Equity (2018 - 2026)

10x Genomics has disclosed Common Equity across 9 years of filings, most recently posting $814.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $814.3 million, up 15.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $814.3 million (up 15.2% YoY), and the FY2025 annual result was $796.3 million, up 12.14% from the prior year.
• Common Equity came in at $814.3 million for Q1 2026 at 10x Genomics, up from $796.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $814.3 million in Q1 2026 to a low of $706.9 million in Q1 2025.
• The 5-year median for Common Equity is $775.8 million (2022), against an average of $765.0 million.
• Across the five-year window, Common Equity declined 10.41% in 2024 and gained 15.2% in 2026, its largest moves.
• 10x Genomics' Common Equity stood at $805.7 million in 2022, then slipped by 8.03% to $741.0 million in 2023, then dropped by 4.17% to $710.1 million in 2024, then increased by 12.14% to $796.3 million in 2025, then advanced by 2.26% to $814.3 million in 2026.
• The last three Common Equity figures came in at $814.3 million (Q1 2026), $796.3 million (Q4 2025), and $785.1 million (Q3 2025), per Business Quant data.